Modifying antibiotic treatment strategies in the face of pertussis surge associated to erythromycin resistance in China - 17/05/24
Doi : 10.1016/j.jinf.2024.106174
Wei Shi, Qinghong Meng, Yahong Hu, Kaihu Yao ⁎ 
Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics, Laboratory of Infection and Microbiology, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
⁎Correspondence to: Beijing Children’s Hospital, Capital Medical University, No. 56 Nan Lishi Road, Beijing 100045, China.Beijing Children’s Hospital, Capital Medical UniversityNo. 56 Nan Lishi RoadBeijing100045China
Highlights |
• | Macrolides fail to treat ERBP infections. |
• | TMP-SMZ is recommended for current pertussis treatment in China. |
• | Beta-lactam drugs are effective for most ERBP infections. |
• | Research on other pertussis treatments should be promoted immediately in China. |
Plan
© 2024
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 88 - N° 6
Article 106174- juin 2024 Retour au numéro
Article précédent
- Heterologous and BNT162b2 boosters are more effective than non-mRNA homologous boosters for Omicron
- Angel Paternina-Caicedo, David Santiago Quevedo, Diana Sofía Ríos, Diane Moyano, Nelson Alvis-Guzmán, Nelson Rafael Alviz-Zakzuk, Fernando Salcedo, Javier Ramírez-Suarez, Adrian D. Smith, Fernando De la Hoz-Restrepo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?